share_log

JP Morgan Maintains Neutral on Biogen, Lowers Price Target to $210

Benzinga ·  Nov 4 22:37  · Ratings

JP Morgan analyst Chris Schott maintains Biogen (NASDAQ:BIIB) with a Neutral and lowers the price target from $220 to $210.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment